NCT04357717 is a clinical trial of ExoDx Prostate in Prostate Cancer, sponsored by Exosome Diagnostics, Inc..

Who is sponsoring NCT04357717?

NCT04357717 is sponsored by Exosome Diagnostics, Inc..

What drugs are being tested in NCT04357717?

Interventions in NCT04357717: ExoDx Prostate.

What condition does NCT04357717 study?

NCT04357717 studies Prostate Cancer.

Is NCT04357717 still recruiting?

NCT04357717 is currently terminated. Last updated 31 March 2022.

Last reviewed 2022-03-31 · How we verify

NCT04357717

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting

Terminated Last updated 31 March 2022

What this trial tests

trial testing ExoDx Prostate in Prostate Cancer in 150 participants. Terminated before completion.

Timeline

15 March 2020

Primary endpoint
1 September 2021

1 September 2021

Quick facts

Lead sponsor	Exosome Diagnostics, Inc.
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	150
Start date	15 March 2020
Primary completion	1 September 2021
Estimated completion	1 September 2021
Sites	2 locations across United States

Drugs / interventions tested

ExoDx Prostate

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Exosome Diagnostics, Inc. — full company profile →

Who can join

50 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is designed to confirm the performance of the ExoDx Prostate test in prior negative biopsy patients now presenting for a repeat prostate biopsy. Note: ExoDx Prostate test results are collected for correlation to biopsy results and are not disclosed to the physician or study subject.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Cancer-Derived Exosomes: Their Role in Cancer Biology and Biomarker Development.
Kok VC, Yu CC. · · 2020 · cited 318× · PMID 33116515 · DOI 10.2147/ijn.s272378
Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications.
Huda MN, Nafiujjaman M, Deaguero IG, Okonkwo J, et al · · 2021 · cited 160× · PMID 33988964 · DOI 10.1021/acsbiomaterials.1c00217
Clinical applications for exosomes: Are we there yet?
Perocheau D, Touramanidou L, Gurung S, Gissen P, et al · · 2021 · cited 101× · PMID 33751579 · DOI 10.1111/bph.15432
The Landscape of Exosomes Biogenesis to Clinical Applications.
Al-Madhagi H. · · 2024 · cited 28× · PMID 38681093 · DOI 10.2147/ijn.s463296
Exosomes: Insights and therapeutic applications in cancer.
Panigrahi AR, Srinivas L, Panda J. · · 2022 · cited 27× · PMID 35551002 · DOI 10.1016/j.tranon.2022.101439
Global requirements for manufacturing and validation of clinical grade extracellular vesicles.
Thakur A, Rai D. · · 2024 · cited 24× · PMID 40027307 · DOI 10.1016/j.jlb.2024.100278
Engineered and Mimicked Extracellular Nanovesicles for Therapeutic Delivery.
Poinsot V, Pizzinat N, Ong-Meang V. · · 2024 · cited 16× · PMID 38607173 · DOI 10.3390/nano14070639
Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine.
Meehan J, Gray M, Martínez-Pérez C, Kay C, et al · · 2021 · cited 14× · PMID 34357131 · DOI 10.3390/jpm11070664

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Exosome Diagnostics, Inc. trials

Trials by the same sponsor.

NCT04720599 — Clinical Evaluation of ExoDx Prostate(IntelliScore) in Men Presenting for Initial Prostate Biopsy · completed
NCT03235687 — Decision Impact Trial of the ExoDx Prostate (IntelliScore) · NA · unknown
NCT03031418 — Clinical Evaluation of the 'ExoDx Prostate IntelliScore' (EPI) · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04357717 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Exosome Diagnostics, Inc.
Last refreshed: 31 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04357717.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing